Factors predictive of mortality in a cohort of women surgically treated for breast cancer from 1997 to 2014. Issue 2 (August 2016)

• Record Type: Journal Article
• Authors: García-Fernández, Antonio; Barco, Israel; Fraile, Manel; Lain, José M.; Carmona, Ana; Gonzalez, Sonia; Pessarrodona, Antoni; Giménez, Nuria; García-Font, Marc
• Is Part Of: International journal of gynaecology and obstetrics. Volume 134:Issue 2(2016:Aug.)
• Page Start: 212
• Page End: 216
• Publication Date: 2016-08
• Subjects: Breast cancer -- Mass screening -- Mortality -- Survival; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1016/j.ijgo.2016.02.014
• Languages: English
• ISSNs: 0020-7292

Abstract

Abstract: Objective: To determine whether previously reported factors predictive of breast cancer mortality are effectively linked with mortality, particularly breast-cancer-specific mortality. Methods: In a prospective study, clinical, surgical, and follow-up data were assessed for consecutive patients with breast cancer who underwent surgery between 1997 and 2014 at two centers in Barcelona, Spain. Predictors of mortality were assessed by multivariate analysis. Results: Overall, 2134 patients were treated for 2206 breast tumors. Overall mortality was 15.0% (n=319), and breast-cancer-specific mortality was 9.0% (n=191). On multivariate analysis, the most significant factors associated with breast-cancer-specific mortality were clinical stage, inmunohistochemical profile, locoregional relapse, and lymphovascular invasion (all P <0.001). Age at onset, participation in the mass-screening program, histologic grade, and multicentricity were not significant. Patients with three or more positive axillary nodes sustained a specific mortality significantly higher than did node-negative patients or those with fewer than three positive nodes. Conclusion: Factors predictive of breast cancer mortality were clinical stage, locoregional relapse, molecular classification, lymphovascular invasion, and neoadjuvant chemotherapy. As a single factor, nodal disease becomes relevant only when three or more lymph nodes are involved.